Select a medication above to begin.
Atzumi
dihydroergotamine nasal
Black Box Warnings .
Peripheral Ischemia w/ Concomitant Strong CYP3A4 Inhibitor Use
serious and/or life-threatening peripheral ischemia possible when given in combo w/ strong CYP3A4 inhibitors incl. protease inhibitors and macrolide antibiotics; CYP3A4 inhibition incr. serum levels and risk for vasospasm leading to cerebral ischemia and/or ischemia of extremities; concomitant use w/ strong CYP3A4 inhibitors contraindicated
Adult Dosing .
Dosage forms: PWDR: 5.2 mg per device
migraine, acute
- [5.2 mg intranasally x1]
- Max: 10.4 mg/day; Info: may repeat dose x1 after 1h; safety not established w/ doses >20.8 mg/wk or >62.4 mg/mo
renal dosing
- [see below]
- mild-moderate impairment: not defined; severe impairment: contraindicated
- HD/PD: not defined
hepatic dosing
- [see below]
- mild-moderate impairment: not defined; severe impairment: contraindicated
Peds Dosing .
Peds dosing is currently unavailable or not applicable for this drug.